Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 08, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: ...

The vaccines are intended to be developed for use against Marburg virus and Sudan ebolavirus, two hemorrhagic fevers in the ...

The US Department of Health and Human Services is weighing whether to fund new Marburg and Sudan Ebola virus vaccines even as Secretary Robert F. Kennedy Jr. overhauls the US immunization landscape, ...

Basilea already secured $29 million to develop its antifungals fosmanogepix and BAL2062, and the Swiss company announced this morning that it has confirmed it will also receive its next tranche of $39 ...

As Synedgen's Chief Executive Officer and Chief Scientific Officer, Dr. Saward will continue to lead the company to deliver on the successful partnership with Biomedical Advanced Research Agency (BARD ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

Galapagos announces leadership transition. European biotechnology company Galapagos completed a significant leadership ...

The full approval of Spikevax covers children aged six months through 11 years who are at increased risk for severe COVID-19, transitioning the vaccine from emergency use to full licensure.

Organs-on-a-chip are miniature devices that use human cells to mimic organs. Harvard bioengineer Donald Ingber and colleagues demonstrated that cells configured into a liver-on-a-chip, for ...

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an initial investment of approximately $55 million for rapid development of VIR-2482, the Vir ...